CTRI/2021/03/032385尚未招募未知
Comparing efficacies of Combinations of Vitamin D3 and Magnesium,Cilnidipine and Telmisartan therapies for reduction in severity of COVID-19 disease using Arterial Stiffness as a clinical marker:A Randomized, Parallel group Comparative Study. - ASCOTH Study
AIIMS Patna0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •RT PCR proved COVID-19 positive patients admitted in AIIMS Patna
- •Age >= 18 years < 70 years
排除标准
- •1. Patients with severe CAD
- •2.Congestive heart failure(CHF)
- •3.Stage II hypertension
- •4.Hypotension
- •5.Patients on insulin, Diabetic Neuropathy,
- •6.Diabetic Keto acidosis
- •7.Stroke and peripheral arterial disorder
- •8.Pre-existing Cardiovascular disease
- •9.Recent MI
- •10.Cardiac transplant within the last 12 months
- •11.Pregnancy
- •12. Patient with peripheral Edema
- •13. Patient with Cardiac Arrhythmia
研究者
相似试验
招募中
1 期
Efficacy comparison of two doses of vitamin D3 in critically ill patients undergoing continuous renal replacement therapy - NephroDVitamin D3 deficiencyMedDRA version: 20.0Level: PTClassification code 10047626Term: Vitamin D deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-006789-19-PLSK w Opolu138
进行中（未招募）
1 期
Efficacy comparison of two doses of vitamin D3 in critically ill patients undergoing continuous renal replacement therapy - NephroDVitamin D3 deficiencyMedDRA version: 20.0Level: PTClassification code: 10047626Term: Vitamin D deficiency Class: 100000004861CTIS2024-510834-42-00niwersytecki Szpital Kliniczny W Opolu138
已完成
不适用
The effect of vitamin D3 on the obesitydrug induced obesity.Use additional external cause code (Chapter XX), if desired, to identify drug.IRCT2014122520430N1Ahvaz Unversity Of Medical Science50
已完成
不适用
Therapeutic regimens for Vitamin D3 deficiencyVitamine D deficiency.Vitamin D deficiencyIRCT2016040527227N1Tarbiat Modares University of Medical Science, Tehran200
招募中
3 期
Efficiency of Vitamin D Supplements in CLBPCTRI/2022/05/042870Pulse Pharmaceuticals Pvt Ltd